Abstract:
As per Indian statistical data neonatal mortality rate is very high (32%) especially because of prematurity. Premature neonatal mortality rate due to RDS is very high i.e.75%. Such preterm neonates with RDS require surfactant therapy and ventilator support quite frequently. This is very expensive and need trained medical staff. At many places trained medical staff is not available and /or patient cannot afford such expensive treatment. Hence saving such preterms seems difficult. Interventions which can improve surfactant production by such preterm neonates remain the ray of hope. Recognition of the surfactant stimulatory and anti-inflammatory properties of ambroxol has led to resurgence of interest in this molecule in the management of difficult to treat RDS in preterm neonates. Because of this fact some of units of NICU are using ambroxol with the conventional treatment of RDS in preterm neonates. Some studies have shown the good results of aerosolized ambroxol in the management of RDS and there are very few studies available regarding the easy, economic and ideal treatment module for RDS. Hence it is worthwhile to analyze the results of aerosolized ambroxol incorporating protocol and a protocol without its use, so as to establish the usefulness of ambroxol in lowering the RDS incidence and its related deaths and also its usefulness in lowering the neonatal sepsis. In the developing countries such simple, inexpensive and easily applicable intervention may have place in neonatal care in future.
